Abstract

We aimed to determine whether clinical examination could adequately ascertain the volume of tissue to be resected during breast-conserving surgery after neoadjuvant therapy. We reviewed the clinical reports of 279 patients with histologically diagnosed invasive breast carcinomas treated with neoadjuvant therapy followed by surgery or with primary surgery alone. We estimated volumes of excised tissues, the volume of the tumor mass and the optimal volume required for excision based on 1 cm of clear margins. The actual excess of resected volume was estimated by calculating the resection ratio measured as the volume of the resected specimen divided by the optimal specimen volume. The study endpoints were to analyze the extent of tissue resection and to ascertain the effect of excess resected tissue on surgical margins in both groups of patients. The median tumor diameter was 2.0 and 1.5 cm in the surgery and neoadjuvant therapy groups, respectively. The median volume of resected mammary tissue was 64.3 cm³ in the primary surgery group and 90.7 cm³ in the neoadjuvant therapy group. The median resection ratios in the primary surgery and neoadjuvant therapy groups were 2.0 and 3.3, respectively (p<0.0001). Surgical margin data were similar in both groups. Comparison of the volume of resected mammary tissues with the tumor diameters showed a positive correlation in the primary surgery group and no correlation in the neoadjuvant therapy group. Surgeons tend to excise large volumes of tissue during breast-conserving surgery after neoadjuvant therapy, thereby resulting in a loss of the correlation between tumor diameter and volume of the excised specimen.

Highlights

  • Breast-conserving surgery (BCS) is the standard treatment for early-stage breast cancer patients

  • We assessed some aspects of the volume of resected breast tumor tissues in patients receiving neoadjuvant therapy who underwent BCS

  • To achieve similar clear margin ratios, surgeons excised a larger volume of tissue from patients treated with neoadjuvant therapy than from patients treated with primary surgery

Read more

Summary

Introduction

Breast-conserving surgery (BCS) is the standard treatment for early-stage breast cancer patients. Long-term follow-up studies have reported comparable disease-free and overall survival rates between patients undergoing mastectomy and BCS1,2. Use of neoadjuvant therapy is an option for increasing the rate of breast-conserving surgery in breast cancer patients[3]. Patients initially scheduled to undergo mastectomy achieve comparable control of focal lesions and favorable disease-free and overall survival rates after undergoing neoadjuvant therapy followed by BCS4-7. BCS results in a better cosmetic outcome than mastectomy, alleviating post-surgical psychological stress. BCS is the least invasive surgical technique for breast cancer treatment, cosmetic outcomes vary widely. Many factors affect cosmetic outcomes after BCS. The volume of excised breast tissue is the most important factor that affects patient satisfaction regarding cosmetic outcomes after BCS8-11

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call